Blogger Widgets

...

TRANSLATE AS YOU LIKE

November 17, 2012

Regulatory Framework for Medical Devices in India

India has emerged as one of the leading markets for pharmaceutical products. Increase in the private healthcare infrastructure, widening rural markets, and inclusion of newer technologies have placed healthcare as an independent sector in India. With privatization of healthcare, the medical devices sector is growing too.
In order to regulate the import, manufacture, distribution and sale of drugs and cosmetics, the Drugs and Cosmetics Act, 1940 (“D&C, Act”) was introduced in India in 1940. However, no separate legislation/regulation has been enacted for regulating the import, manufacture, distribution or sale of medical devices in India till date by the Government of India.
The Central Drugs Standard Control Organization (CDSCO) is the key medical regulatory organization in India. Since 2006, both the Indian Department of Science and Technology and the Ministry of Health and Family Welfare have sought to completely restructure the regulations for the medical devices. Till date, neither of these attempts has been successful. Medical device market is quite diverse which includes medical and diagnostic equipment; medical implants like heart valve and cardiac stents, pacemakers, cannulae, knee joints; and lower end plastic disposables, blood bags, IV sets, syringes etc. In light of its widespread applicability, overall medical device market is experiencing reasonable growth.
Historically, most Indians had very limited access to any type of modern medical service. Today, however, the situation is much improved. There is a growing awareness about health issues within India, an increasing demand for quality care at affordable prices, further the Indian Healthcare industry is in a steady growth trajectory and is expected to grow in the next few years.
The Indian economy is worth about US$1,243 billion and rapidly getting bigger. The GDP growth reached 9% in the year to March 2008. The 2010-11 budget extended the coverage to another 20% of the Indian population covered by the National Rural employment Guarantee Act (NREGA) programmes, who have worked for more than 15 days during the preceding financial year.Budget 2010-11 also allocated US$ 2,920 million under the National Rural Health Mission (NRHM), an increase of 15% over the previous year.
Regulations on Medical Devices in India
 Undoubtedly, the medical devices and surgical instruments are currently not covered under the regulatory framework in India. However, any device which is intended for internal or external use in the diagnosis, treatment, mitigation or prevention of disease or disorder in human beings or animals, as may be specified by the Central Government by notification in the Official Gazette would be considered as a drug under the D&C Act and provisions of D&C Act and Rules made therein would be applicable on such device. From time to time, Ministry of Health and Family Welfare, Government of India vide gazette notifications has notified certain medical devices as drugs under the D&C Act.
 Prior to 2005, only medical devices such as disposable hypodermic syringes, tubal rings, condoms, metered dose inhalers, were required to be registered in India. In 2005, the Ministry of Health and Family Welfare (MOHFW) vide gazette notification dated 6 October 2005 further notified 10 sterile devices (“Notified Medical Devices”) to be considered as drugs and consequently regulated their import, sale and manufacture under Section 3(b) (iv) (defined below) of the D&C Act.
Regulating Authority for Notified Medical devices
In India, the Central Drugs Standard Control Organization (‘CDSCO’) is the main regulatory body currently regulating import, sale and manufacture of medical devices which have been notified as drugs by virtue of Section 3(b) (iv) of the D&C Act.The CDSCO lays down standards of drugs, cosmetics, diagnostics and devices and issues licenses to drug manufacturers and importers. It also lays down regulatory measures, amendments to Acts and Rules and regulates market authorization of new drugs, clinical research in India and standards of imported drugs etc. The CDSCO has setup a separate division which is called Medical Device Division in order to facilitate mattes related to Notified Medical Devices.
New Proposed Medical Devices Regulation Bill
 In 2006, the Medical Devices Regulation Bill (MDRB) was proposed by the Ministry of Science and Technology. The MDRB was designed to consolidate laws related to medical devices and establish the Medical Device Regulatory Authority of India (MDRA). This proposal was aimed at establishing and maintaining a national system of controls for the quality, safety and availability of medical devices in India. If enacted, the MDRB will govern all medical devices throughout India. Companies wishing to import devices into India or manufacture products locally will have to comply with the design, manufacturing, packaging, labeling, import, sale, use, and disposal requirements of the MDRB. Also the bill will expand the list of products requiring registration.
 The Bill provides for the creation of a Medical Device Regulatory Authority which has been empowered with extensive powers relating to fining and imprisoning defaulters. Besides looking to harmonize the standards in accordance with the global norms to push the export potentials, the Bill also seeks to lay down concrete norms on import of devices and their conformity with the Indian standards. Standards notified by the Bureau of Indian Standards or other international standards making bodies like International Organization for Standardization (ISO), may be incorporated for harmonization. The Bill seeks to regulate the design, manufacture, packaging, labelling, import, sale, usage and disposal of medical devices in India.
 With a view to raise the level of control on Medical Devices, the Drug Technical Advisory Board (DTAB) in India has submitted the final draft of the guidelines on medical devices and has recommended strict implementation of Indian Conformity Assessment Certificate (ICAC) for the medical devices manufactured, imported and marketed on Indian market under Schedule M III of Drugs & Cosmetics Rules 1945. The Medical Devices have been classified into Class A, B, C & D as per their level and intended use. It is provided that all Medical Devices sold in India (except for custom made devices, meant for a particular patient use) should, as a general rule, bear the Indian Conformity Assessment Certificate mark (ICAC) to indicate their conformity with the provisions of this schedule.
Proposed New Clinical Trial Regulations 
Additionally, the MDRB discusses clinical trials and Clinical Research Organizations (CROs) in India. If the bill is approved, some high-risk medical devices will require local clinical trials in India in addition to foreign clinical data. In general, more-stringent regulations will apply to CROs and clinical trials.
My Comment:
The Indian medical devices and supplies market is at a nascent stage and was estimated at US$2.75 billion in 2008. This is about 1.25% of the global medical devices and supplies market of around US$220 billion in 2008. By 2012, India’s medical devices market is expected to nearly double to around US$5 billion.The production of low value medical supplies and disposables is dominated by domestic manufacturers, whereas the high end medical equipment is generally imported. In the future, due to the huge market opportunity in India, more and more foreign medical device companies are expected to explore Indian market for their products.
With an evolving regulatory situation, medical device companies are required to stay up-to-date in order to achieve success in India. The Indian government is working on a comprehensive regulatory framework for the medical device sector. India’s health authorities plan to issue a set of guidelines to define and regulate medical devices as a separate category.
 The growth of Indian medical devices industry is driven by a host of factors and is sure to see exponential growth in the coming years. Some market drivers for this industry are:
  1. An increase in the Gross Domestic Product growth of the Indian economy
  2. Increase in the Healthcare Expenditure
  3. Improvement of overall health status
  4. Changing of demand pattern for medical devices in India due to a rise of lifestyle-related diseases such as diabetes, cardiovascular disease etc.
  5. Increasing of Medical Tourists
  6. Increasing of medical infrastructures like hospitals, specialized diagnostic centers, laboratories
In a nutshell, continued flow of investment in private sector infrastructure has resulted in a steady increase in the market for medical equipments and supplies. It is estimated that the market will continue to grow. Further, the recent liberalization of trade and investment laws makes India one of the most promising markets for medical device manufacturers. It is predicted that India will be the most populous country in the world by 2050. India will make its mark as a growing market, potential partner in manufacturing and R&D, and as a preferred destination for clinical trials.

Source: CDSCO
by
Dr.Akshaya Srikanth,
Pharm.D India

November 15, 2012

Drug Induced Liver Injury (DILI)

The liver is the first stop on the path a drug takes after oral ingestion. From the liver’s “point of view”, drugs are like other exogenous agents and are handled by the liver for excretion. Absorption is largely into the portal system which brings intestinal blood to the liver where transformation and metabolism occur in preparation for elimination (e.g. in the urine, in bile etc.). Metabolism may occur in two phases: Phase I is preparation by oxidation, reduction, hydrolysis and other reactions of the compound for action in Phase II. The second phase occurs in the cytosol and involves reactions catalyzed by transferase enzymes. The cytochrome P-450 system plays a major role in this. The study of the P-450 system allows some degree of prediction of possible hepatotoxicity.
Liver toxicity is usually thought of as producing damage to the liver parenchymal cells (hepatocytes) but toxicity can also be produced affecting biliary cells, kupffer cells, fat storing cells etc.

Adverse events can be classified as Type A which represents pharmacologic effects and are often (but not always) predictable. There may be a dose response effect with worsening of the toxicity only after a particular blood level or threshold is reached of the drug or its metabolites. The classic example of this is acetaminophen (paracetamol) toxicity which is toxic only if more than about 6-8 grams a day are taken. Type B reactions are idiosyncratic and unpredictable. Many drugs can do this.
The toxicity produced by drugs can be of various types. Very common is inflammation (hepatitis) with cell necrosis and inflammation. Viruses can produce hepatitis also of course. Drug induced hepatitis may be acute (many drugs, alcohol) or chronic (e.g. methyldopa, alcohol). It may be catastrophic or mild. Drugs may cause bile flow impairment with or without inflammation and with or without bile duct damage. Oral contraceptives, allopurinol and chlorpromazine may produce cholestasis as can alcohol. Other drug toxicities include fatty liver (steatosis), granuloma production and injury to the blood vessels. Finally long exposure to some exogenous agents including drugs can produce malignancies of the liver.
Many drugs may produce mild elevations of transaminases (enzymes) such as aspartate transaminase (AST also known as SGOT), alanine aminotransferase (ALT also known as SGPT), GGTP, and alkaline phosphatase which are often called “liver enzymes” or “liver function tests”. This is something of a misnomer as other non-hepatic problems can raise these enzymes. Bilirubin can also be elevated with liver toxicity.
Mild reversible elevations of these lab tests are usually benign and reverse after the drug is stopped or sometimes decrease or return to normal even if the drug is continued. The real issue is to prevent severe, irreversible and sometimes fatal liver toxicity.
The clinical spectrum of liver toxicity can range from no signs or symptoms at all to mild, moderate, severe and fatal. There is no way to absolutely know that a drug induced liver toxicity. Even liver biopsy may not prove it.
There are some risk factors including the underlying medical condition, the very old or young, bad nutritional status, nutritional status, alcohol use (amount, chronic, acute) and concomitant medications. The frequency of severe liver toxicity may be less than one case per 10,000 which means that this will not be identified before marketing when only a few thousand patients at most are examined in clinical trials.
Unfortunately there is usually no way to predict which patients will get the severe or fatal types of liver injury. The incidence and amount of AST/ALT elevation, the time to onset or the type of injury do not always predict the risk and outcome of liver injury. Thus one cannot always take comfort from the fact that the liver enzymes were “only” twice normal.
by
Dr.Akshaya Srikanth
Pharm.D India